218 related articles for article (PubMed ID: 34583518)
21. Editorial: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy.
Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):100. PubMed ID: 26791134
[No Abstract] [Full Text] [Related]
22. 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.
Ruebsam F; Tran CV; Li LS; Kim SH; Xiang AX; Zhou Y; Blazel JK; Sun Z; Dragovich PS; Zhao J; McGuire HM; Murphy DE; Tran MT; Stankovic N; Ellis DA; Gobbi A; Showalter RE; Webber SE; Shah AM; Tsan M; Patel RA; Lebrun LA; Hou HJ; Kamran R; Sergeeva MV; Bartkowski DM; Nolan TG; Norris DA; Kirkovsky L
Bioorg Med Chem Lett; 2009 Jan; 19(2):451-8. PubMed ID: 19054673
[TBL] [Abstract][Full Text] [Related]
23. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic characterization of 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone, a novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor in rats.
Zheng Z; Seo H; Kwak HJ; Kim KY; Ahn JH; Bae MA; Song JS
Arch Pharm Res; 2016 Apr; 39(4):492-498. PubMed ID: 26780247
[TBL] [Abstract][Full Text] [Related]
25. Proteolysis-targeting chimeras for targeting protein for degradation.
Qi J; Zhang G
Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
[TBL] [Abstract][Full Text] [Related]
26. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
[TBL] [Abstract][Full Text] [Related]
27. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
28. Property-based design of KDR kinase inhibitors.
Fraley ME; Hoffman WF; Arrington KL; Hungate RW; Hartman GD; McFall RC; Coll KE; Rickert K; Thomas KA; McGaughey GB
Curr Med Chem; 2004 Mar; 11(6):709-19. PubMed ID: 15032725
[TBL] [Abstract][Full Text] [Related]
29. Monovalent protein-degraders - Insights and future perspectives.
Cornella-Taracido I; Garcia-Echeverria C
Bioorg Med Chem Lett; 2020 Jun; 30(12):127202. PubMed ID: 32331933
[TBL] [Abstract][Full Text] [Related]
30. An activity-based probe developed by a sequential dehydroalanine formation strategy targets HECT E3 ubiquitin ligases.
Xu L; Fan J; Wang Y; Zhang Z; Fu Y; Li YM; Shi J
Chem Commun (Camb); 2019 Jun; 55(49):7109-7112. PubMed ID: 31157339
[TBL] [Abstract][Full Text] [Related]
31. E3 ligases: a potential multi-drug target for different types of cancers and neurological disorders.
Saravanan KM; Kannan M; Meera P; Bharathkumar N; Anand T
Future Med Chem; 2022 Jan; 14(3):187-201. PubMed ID: 35100004
[TBL] [Abstract][Full Text] [Related]
32. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Small Molecule WWP2 Ubiquitin Ligase Inhibitors.
Watt JE; Hughes GR; Walpole S; Monaco S; Stephenson GR; Bulman Page PC; Hemmings AM; Angulo J; Chantry A
Chemistry; 2018 Dec; 24(67):17677-17680. PubMed ID: 30207403
[TBL] [Abstract][Full Text] [Related]
34. Development and characterisation of SMURF2-targeting modifiers.
Manikoth Ayyathan D; Levy-Cohen G; Shubely M; Boutros-Suleiman S; Lepechkin-Zilbermintz V; Shokhen M; Albeck A; Gruzman A; Blank M
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):401-409. PubMed ID: 33430646
[TBL] [Abstract][Full Text] [Related]
35. Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase.
Scott DC; Hammill JT; Min J; Rhee DY; Connelly M; Sviderskiy VO; Bhasin D; Chen Y; Ong SS; Chai SC; Goktug AN; Huang G; Monda JK; Low J; Kim HS; Paulo JA; Cannon JR; Shelat AA; Chen T; Kelsall IR; Alpi AF; Pagala V; Wang X; Peng J; Singh B; Harper JW; Schulman BA; Guy RK
Nat Chem Biol; 2017 Aug; 13(8):850-857. PubMed ID: 28581483
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of the first potent, selective, and cell penetrating adenosine 5'-monophosphate deaminase inhibitors.
Bookser BC; Kasibhatla SR; Appleman JR; Erion MD
Adv Exp Med Biol; 1998; 431():853-7. PubMed ID: 9598184
[TBL] [Abstract][Full Text] [Related]
37. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.
Kannt A; Đikić I
Cell Chem Biol; 2021 Jul; 28(7):1014-1031. PubMed ID: 33945791
[TBL] [Abstract][Full Text] [Related]
38. Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation.
Ottis P; Toure M; Cromm PM; Ko E; Gustafson JL; Crews CM
ACS Chem Biol; 2017 Oct; 12(10):2570-2578. PubMed ID: 28767222
[TBL] [Abstract][Full Text] [Related]
39. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
40. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
Hu Y; Xiang JS; DiGrandi MJ; Du X; Ipek M; Laakso LM; Li J; Li W; Rush TS; Schmid J; Skotnicki JS; Tam S; Thomason JR; Wang Q; Levin JI
Bioorg Med Chem; 2005 Dec; 13(24):6629-44. PubMed ID: 16216515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
